Immuneering Co. (NASDAQ:IMRX) Receives $12.80 Average Target Price from Analysts

Immuneering Co. (NASDAQ:IMRX) has been assigned an average rating of “Hold” from the eight ratings firms that are currently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, three have issued a hold rating and four have issued a buy rating on the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $12.80.

IMRX has been the subject of several research analyst reports. Chardan Capital reiterated a “buy” rating and set a $13.00 target price on shares of Immuneering in a research report on Wednesday, January 8th. Needham & Company LLC reaffirmed a “buy” rating and set a $15.00 price objective on shares of Immuneering in a report on Monday, January 13th. Finally, Morgan Stanley downgraded shares of Immuneering from an “equal weight” rating to an “underweight” rating in a report on Friday, December 13th.

Institutional Trading of Immuneering

Several hedge funds have recently modified their holdings of the company. Vontobel Holding Ltd. bought a new position in shares of Immuneering in the 3rd quarter valued at about $25,000. Corsair Capital Management L.P. purchased a new stake in Immuneering during the third quarter valued at approximately $25,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Immuneering in the 2nd quarter valued at approximately $44,000. Tidemark LLC purchased a new position in shares of Immuneering in the 3rd quarter worth approximately $129,000. Finally, HighTower Advisors LLC increased its position in shares of Immuneering by 21.4% during the 3rd quarter. HighTower Advisors LLC now owns 53,360 shares of the company’s stock valued at $132,000 after purchasing an additional 9,400 shares during the last quarter. 67.65% of the stock is owned by hedge funds and other institutional investors.

Immuneering Stock Performance

Shares of IMRX stock opened at $1.91 on Monday. The stock has a fifty day simple moving average of $2.06 and a two-hundred day simple moving average of $1.87. The firm has a market capitalization of $59.31 million, a PE ratio of -0.97 and a beta of -0.36. Immuneering has a 52-week low of $1.00 and a 52-week high of $7.68.

Immuneering Company Profile

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.